June 29, 2012—The association representing hospitals in the 340B drug discount program is urging its 850-plus members and all others enrolled to adopt six principles of responsible program stewardship. The code of conduct drafted by Safety Net Hospitals for Pharmaceutical Access (SNHPA) covers how 340B savings should be used, what charity care should encompass, contract … [Read more...]
U.S. Supreme Court Preserves Health Reform’s 340B Provisions
Justices vote 5-to-4 to largely uphold Affordable Care ActJune 28, 2012—The U.S. Supreme Court's 5-to-4 decision today to largely uphold the constitutionality of the Affordable Care Act (ACA) preserves rural, children's, and cancer hospitals' eligibility to participate in the 340B drug discount program. The Drug Discount Monitor is still analyzing the 193-page decision. … [Read more...]
Octapharma Making IGIV Widely Available at 340B Pricing
Plasma-derived product has been chronically unavailable at a discountJune 28, 2012—Human protein products manufacturer Octapharma USA has announced an initiative to make its octagam 5% immune globulin intravenous (IGIV) therapy for primary immune deficiency widely available to 340B covered entities. "Octapharma is committed to providing therapies to treat life-threatening conditions to all patients, including those who are treated in … [Read more...]
Fla. Lifts Inventory Barrier to 340B Contract Pharmacies
New law will end requirement for physically separate drug stocksJune 21, 2012—Effective July 1, Florida 340B contract pharmacies will no longer have to keep physically separate inventories for 340B and non-340B drugs, under legislation passed by state lawmakers and signed by Gov. Rick Scott (R) this spring. … [Read more...]
Bristol-Myers Squibb Ends Bulk Replenishment for Plavix
Widely-used anti-coagulant came off patent on May 17June 21, 2012—Bristol-Myers Squibb's (BMS) patient assistance foundation has notified hospitals that the drug manufacturer's blockbuster anti-coagulant Plavix is no longer available for bulk replenishment. Plavix also is no longer listed on the foundation's Web site among the medications available at no cost to low-income and uninsured individuals. … [Read more...]
HRSA Publishes More Information About 340B Audits
Document does not include audit protocol or discuss appeals of adverse determinationsJune 21, 2012—The Health Resources and Services Administration (HRSA) has issued a document to give 340B stakeholders a clearer picture of what it is looking for when it audits a 340B covered entity and its overall process for conducting such reviews. The document, however, does not include the actual protocol that HRSA is using to conduct the audits. … [Read more...]
Senate Panel Once Again Approves 0.1% Fee on 340B Drug Purchases
Urges HRSA to release information about audit processes "as soon as possible"June 15, 2012—The Senate Appropriations Committee has passed a fiscal 2013 spending bill for federal health care programs that would maintain the Office of Pharmacy Affairs' (OPA) appropriation at its current $4.47 million and supplement it with another $6 million from a 0.1 percent user fee on 340B drug purchases. In the report that accompanies the bill, the committee … [Read more...]